Clinical Efficacy Of Xiaozhihugan Capsules Combined With Entecavir In Treating CHB Patients With NAFLD

Objective: A series of randomized controlled trials are carried out to investigate the mutual antiviral efficacy of Xiaozhihugan capsules and Entecavir Dispersible Tablets on the treatment of patients with Chronic hepatitis type B and Nonalcoholic fatty liver disease.The experimental results would provide clinical study with empirical evidence.Methods: Based on the random number table method,64 patients,meeting the inclusion criteria,are classified into treatment group(32)and control group(32).With appropriate exercise and dietary guidance,the treatment group is given Xiaozhihugan capsules in combination with Entecavir Dispersible Tablets,while the control group is treated only with Entecavir Dispersible Tablets.The whole treatment lasts 3 months.After treatment,the levels of HBV-DNA,alanine aminotransferase(ALT),serum triglyceride(TG),hepatic fat CAP,fasting blood glucose(GLU),aspartate aminotransferase(AST)and free fatty acid(FFA)are compared before and after treatment.A statistical analysis is made of the experimental data by means of SPSS 19.0.Results: 1.Comparison of the indexes of liver function before and after treatment.For the treatment group,there is significant statistical difference(P<0.01)between the levels of ALT and AST before and after the treatment.The same statistical result is also yielded for the control group(P<0.01).Since there is no obvious difference(P>0.05)between the levels of ALT and AST among the two group members before the treatment,the final data are of comparability.Besides,there is no significant difference(P>0.05)between the levels of ALT and AST among the two group members after the treatment.The above results reveal that the two treatment methods involved in the experiment are of positive effects on improving the liver function indexes of CHB and NAFLD patients.2.Comparison of the indexes of blood lipid before and after treatment.After treatment,the FFA levels of the patients in the treatment group were significantly different from those before treatment(P<0.05),while their TG levels don't show prominent changes(P>0.05).The same experiment phenomenon also occurs in the comparison results among the control group.In addition,there is no obvious difference between the FFA and TG levels,when these data are compared between the treatment group and the control group.This finding is indicative of the comparability of the final experimental data secured after the treatment.The two group patients are significantly different in terms of their FFA levels(P<0.05)and are identical in their TG levels(P>0.05)after the treatment.These results show that both the combination of Xiaozhihugan capsules and Entecavir Dispersible Tablets and the single treatment with Entecavir Dispersible Tablets have positive efficacy on lowering the FFA level of CHB and NAFLD patients.Besides,the former's effects are superior to those of the later.However,these two treatment methods have no prominent effects on patients' TG level.3.Comparison of color Doppler results before and after treatment.Both groups show significant statistical changes in their CAP levels(P<0.05),when their CAP levels are compared before and after treatment respectively.There is no obvious difference between the CAP levels of these two groups before treatment(P>0.05).Therefore,the difference after treatment is statistically valid.Furthermore,the difference in CAP levels between the two groups after treatment is not statistically significant(P>0.05).The above results reveal that the two treatment methods in the treatment group and the control group have positive effects on the improvement of CAP level in CHB and NAFLD patients.But the combination of Xiaozhihugan capsules and Entecavir Dispersible Tablets does not have any advantage over the single Entecavir Dispersible Tablets treatment of improving CAP level.4.Comparison of blood glucose levels before and after treatment.There is no significant difference for both the treatment group and control group,when their GLU levels are compared before and after treatment separately(P>0.05).The two groups don't show obvious statistical difference in GLU levels before treatment(P>0.05).Hence the data after treatment are of valid comparability.Besides,there is no significant difference in GLU levels between the two groups after treatment(P>0.05).The above results indicate that both two treatment methods have no significant effects on the improvement of GLU level.5.Comparison of virus replication before and after treatment.The HBV-DNA levels of both the treatment group and the control group change significantly,before and after treatment(P<0.01).Before treatment,there is no prominent difference in HBV-DNA level between the two groups(P>0.05).Thus,the data after treatment are of high comparability.After treatment,the difference in HBV-DNA levels between the two groups is statistically significant(P<0.01).These findings reveal that the antiviral efficacy of combining Xiaozhihugan capsule and Entecavir Dispersible Tablets is better than the single treatment with Entecavir Dispersible Tablets on CHB patients with NAFLD.Xiaozhihugan capsules could positively enhance the antiviral efficacy of Entecavir Dispersible Tablets.6.Comparison of the factors influencing HBV-DNA level.An analysis is made of factors that may affect HBV-DNA level in this clinical observation.The results show that changes in FFA level of the two groups before and after treatment would exert positive effects on the DNA level(t=2.884,P<0.05),while changes in ALT,AST,TG,CAP,and GLU levels before and after treatment have no effects on DNA level(P>0.05).The above results indicate that FFA level has positive effects on changes in HBV-DNA level.Conclusion: 1.The combination of Xiaozhihugan capsules and entecavir has a positive effect on decreasing ALT and AST levels in patients with CHB and NAFLD,especially increasing ALT normalization rate.2.The combination of Xiaozhihugan capsules and entecavir has a certain positive effect on decreasing the FFA level of patients with CHB and NAFLD.3.The combination of Xiaozhihugan capsules and entecavir has a certain positive effect on decreasing the CAP level in CHB patients with NAFLD,but there is no obvious advantage compared with the control group with entecavir alone.4.Xiaozhihugan capsules may have no effect on improving the GLU level of CHB patients with NAFLD.5.There is a certain positive effect of Xiaozhihugan capsules on improving the antiviral efficacy of entecavir.6.The change of FFA level was negatively correlated with the change of HBV-DNA level in patients with CHB and NAFLD.Decreasing FFA may increase the virological response level in CHB patients with NAFLD.